Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7

Benzinga Newsdesk www.benzinga.com Positive 69.3%

Neg 0% Neu 0% Pos 69.3%

Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.